Clinical trials: Gastrointestinal System--Abnormalities
Cystic Fibrosis
Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential…
- Trial name
- Modulate-CF (NCT04732910)
- Testing
- Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor, Vanzacaftor-Tezacaftor-Deutivacaftor
- Where
- 4 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
ABT-751 in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00036959
- Testing
- ABT-751
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cystic Fibrosis
Sit-to-stand Test in Cystic Fibrosis Children and Adolescents
Cystic fibrosis (CF) is a chronic hereditary respiratory disease. Exercise testing is part of CF patients regular assessment. Cardio-Pulmonary Exercise Testing (CPET) is currently considered as the gold standard to assess…
- Trial name
- NCT03069625
- Testing
- Sit-to-stand test, 6-Minute Walk Test
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- Groupe Hospitalier du Havre
Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease
Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
This is a Phase 2 study sponsored by AzurRx SAS and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease, Cystic Fibrosis of Pancreas
- Trial name
- NCT04302662
- Testing
- MS1819-SD
- Where
- 10 sites in Hungary, Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- AzurRx SAS
Cystic Fibrosis
PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis
Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an increasingly common finding, and the lack of an evidenced-based approach to treatment of NTM disease has been identified as one of the…
- Trial name
- PATIENCE (NCT02419989)
- Where
- 19 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Jewish Health
Biliary Atresia
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
- Trial name
- EMBARK (NCT04524390)
- Testing
- Maralixibat
- Where
- 22 sites in United States, China and 6 more
- Volunteers
- 75 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Hirschsprung Disease
Registry for Hirschsprung Disease of the BELAPS
Registry for Hirschsprung disease of the BELAPS (Belgian Association of Pediatric Surgery) Protocol Short Title/Acronym / Sponsor name BELAPS Principal Investigator Prof. Dr.
- Trial name
- NCT04622410
- Where
- Belgium
- Volunteers
- 432 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cystic Fibrosis
Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function
This study is being done to test a device called micro Sweat Test Patch (mSTP or µSTP). The study team will compare the standard of care (SOC) method of sweat testing with a novel sweat test technique using an integrated micro…
- Trial name
- SWEAT CF (NCT07414810)
- Testing
- micro Sweat Test Patch (mSTP), Sweat Testing using SOC
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Emory University
Cystic Fibrosis
Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL Study
Airway disease, featuring intense inflammation, is the main cause of morbidity and mortality in cystic fibrosis (CF). Mechanisms of CF airway inflammation remain unclear, hampering development of better treatments.This…
- Trial name
- I-BALL (NCT02907788)
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Erasmus Medical Center
Peutz-Jeghers Syndrome
Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report
Our study is a case report of one of the rarest risk factor, Peutz-Jeghers syndrome, of small bowel malignancy detected in a patient with poorly differentiated adenocarcinoma of small bowel(jejunum)
- Trial name
- NCT06242457
- Where
- Ethiopia
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Haramaya Unversity
Cystic Fibrosis
18FDG- PET/CT Contribution to the Assessment of Lesion Severity in Cystic Fibrosis (CF)
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF trans-membrane conductance regulator (CFTR) protein.
- Trial name
- NCT00363402
- Testing
- PET-CT
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
Pulmonary NTM infection is recognized as one of the most challenging infections to treat among people with cystic fibrosis (PwCF), notable for prolonged treatment courses and often poor response to therapy.
- Trial name
- pHALT NTM (NCT05686837)
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis
The purpose of this research study is to provide a novel method for the diagnosis of Cystic Fibrosis (CF). This protocol is designed to test the ability of the cells to regulate the movement of salt and water in people with…
- Trial name
- NCT00589745
- Testing
- Nasal potential difference measurement
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Children's Hospital of Philadelphia
Gastrointestinal Symptoms in Young Infants
Milk-induced Gastrointestinal Symptoms in Infants
Various digestive manifestations are common in infants less than 6 months and have a significant impact on morbidity and quality of life of the family.
- Trial name
- NCT01684319
- Testing
- Formula milk free of cow's milk protein
- Where
- Switzerland
- Volunteers
- 120 people
- Sponsor
- University Hospital, Geneva
Patent Ductus Arteriosus
Brain, Gut and Kidney Blood Flow During Medical Closure of PDA
The purpose of this study is to determine how the medications which are used to close the patent ductus arteriosus (PDA) in preterm infants affect brain, kidney and gut blood flow when compared to infants that are not treated…
- Trial name
- NCT00554307
- Testing
- INVOS Cerebral/Somatic oximeter
- Where
- United States
- Sponsor
- University of Louisville
Cystic Fibrosis
Functional Analysis by Dynamic Imaging of the Respiratory Epithelium in Infants With Cystic Fibrosis
Cystic fibrosis (CF) is characterized by airway inflammation and infection leading to progressive destruction of lungs. One of the most important abnormalities in CF is an abnormal processing of the mutated CFTR protein through…
- Trial name
- NCT01605565
- Testing
- A nasal brushing
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cystic Fibrosis
Fidgety Movements in Cystic Fibrosis
Very low birth weight infants who are at risk for chronic lung diseases may also be at risk for brain anomalies such as increased echogenicity, leukomalacia and intracranial hemorrhage.
- Trial name
- NCT03381157
- Testing
- Observational General Movements Assessments
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Benign Breast Disease, Breast Cancer
Prolactin Receptor and Breast Diseases
Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes.
- Trial name
- Prolacsein (NCT00842465)
- Testing
- blood collection for hormonal status analysis, breast Biopsy or surgery, blood collection
- Where
- France
- Volunteers
- 735 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
Anti-IL5 and Other Biotherapies in Cystic Fibrosis
Our project is to describe retrospectively and prospectively CF patients treated with biotherapy in French CF centers. Main objective: To describe the clinical and paraclinical course of CF patients before and after treatment…
- Trial name
- MAB-CF (NCT04256772)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis
The purpose of this research study is to determine if multiple doses of two inhaled drugs will help Cystic Fibrosis patients whose lungs are infected with a bacteria called Burkholderia dolosa.
- Trial name
- NCT00547053
- Testing
- Amiloride Solution for Inhalation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Boston Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.